AlzeCure Pharma

Activities: Drug Delivery Research & Development

Trending Articles

  1. Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research...
  2. Manufacturing Chemist Stand Side with Piramal Pharma Solutions We discover what exhibitors at CPHI 2025 are showcasing LIVE!
  3. SGS achieves breakthrough in infectious disease research with launch of novel RSV A-strain Derived from a 2015 circulating strain, SGS's novel RSV-A challenge agent offers a closer match to circulating RSV viruses than strains currently used in clinical research
  4. One in four European pharma companies at risk of regulatory breaches according to NSF research The independent survey exposed significant gaps in quality systems, supply chain oversight and data integration, just as EU GMP regulations continue to tighten
  5. IWK introduces machine to produce 100% cardboard blister packaging CABLIblue 870 features innovative “card-to-card” technology for recyclable, fiber-based blisters

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

Related Content

Research & Development

AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment

AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy
Regulatory

AlzeCure's pain project ACD440 granted orphan drug status in the US by the FDA

AlzeCure Pharma announces that the US Food and Drug Administration (FDA) has granted the company's application for orphan drug status for the clinical pain candidate drug ACD440
Regulatory

AlzeCure's topical pain gel gets into the FDA good books following Phase II trial

The FDA has stated its positive opinion on a preIND application submitted ahead of AlzeCure's Orphan Drug Designation application
Training & Education

AlzeCure releases paper on Trk receptor modulation for Alzheimer's disease

The paper details the potential of Trk receptor modulation in treating neurological conditions such as Alzheimer's and Parkinson's disease
Research & Development

AlzeCure elect Dr Jan Lundberg as a new board member

Dr Lundberg has experience in leadership position in global pharmaceutical companies, including AstraZeneca and Eli Lilly

AlzeCure's Alzheimer's project NeuroRestore ACD856 granted an additional patent

ACD856 and other substances in the NeuroRestore platform stimulate several important signalling systems and signalling molecules in the brain such as BDNF and NGF
Manufacturing

AlzeCure Pharma receives patent for anti-Alzheimer's drug

ACD856 and other substances in the NeuroRestore platform stimulate several important signalling systems and signalling molecules in the brain
Subscribe now